In a significant move toward greater transparency in drug research Johnson  Johnson said it signed an agreement with Yale University under which the company will share detailed clinical trial data from hundreds of drugs and other products with outside academic researchers Under the unusual arrangement Yale will vet proposals from scientists who want to conduct safety efficacy and other studies of the treatments and determine without input from JJ which researchers will be given access to the clinical data